An appearance of statin did not only cause fall of onset rate and the death rate of coronary arteries disease, but also a fall of the total death rate. These results are restraint of cardiovascular event, development and regression restraint of plaque, function improvement of plaque constitution cells, resulting in the decrease of the total death. However, most of the clinical lipid intervention trial were European and USA results, and there was a difference of a quantity of dosage, too, and results in a Japanese were waited for. Results of a clinical lipid intervention trials in a Japanese appeared by degrees, too though a little too late. From those results, it is proposed that hyperlipidemia is managed whether there are several risk factors of atherosclerosis except hyperlipidemia. Needless to say, it is for the greatest purpose of hyperlipidemia treatment to prevent the development and progression of atherosclerosis. Therefore, it is necessary to treat hyperlipidemia after having fully understood the function mechanism of lipid-lowering agents and after having thought about the morbid state of a patient. In addition, on the occasion of a combination treatment it is necessary to administer it after having understood the each other's function mechanism.